William Grossman, Interim Chief Medical Officer at enGene Therapeutics Inc. (ENGN), bought 5,102 shares at $1.97 ($10K) on 2026-09-22, disclosed to the SEC on 2026-09-24.
Interim Chief Medical Officer William Grossman purchased $10,051 worth of shares at $1.97, marking the largest insider purchase in the company's history. This significant buy suggests the company's leadership believes the stock is undervalued following recent volatility.
The stock has rallied 4.99% over the last 5 days and is up 6.95% over the last 30 days, trading at $2.00, which is 41.84% above its 52-week low of $1.41.
1) enGene Eyes 2027 Approval as Detalimogene Targets Expanding Bladder Cancer Market (MarketBeat, 2026-08-13); 2) enGene Highlights 2026 Data Catalysts, BLA Plans for Bladder Cancer Gene Therapy at Barclays Conference (MarketBeat, 2026-03-15); 3) enGene Maps BLA by End-2026, Targets 2027 Launch for Lead NMIBC Therapy at Oppenheimer Conference (MarketBeat, 2026-02-28).
The stock is down 71.35% over the last year and faces scrutiny from shareholder-rights investigations following mixed LEGEND Phase 2 durability data that triggered analyst downgrades.
Nothing distinguishes this filing.
| Filing → |
| RCUS | SELL | 2021-03-18 | $149K | — | Filing → |
| RCUS | SELL | 2020-12-18 | $133K | — | Filing → |
| RCUS | BUY | 2020-08-04 | $4K | — | Filing → |